L. Kroger

发表

Antibody responses to macrocycles in lymphoma.

G. Denardo, S. Denardo, C. Meares, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy.

K. Lamborn, G. Denardo, S. Denardo, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.

K. Lamborn, G. Denardo, S. Denardo, 1994, Cancer research.

Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3)

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a model

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

Strategies for developing effective radioimmunotherapy for solid tumors.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.

E. Perez, K. Lamborn, G. Denardo, 1998, Anticancer research.

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.

K. Lamborn, G. Denardo, S. Denardo, 2000, Cancer biotherapy & radiopharmaceuticals.

Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo.

S. Denardo, D. Kukis, C. Meares, 1992, Bioconjugate chemistry.

Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.

G. Denardo, S. Denardo, S. Shen, 1998, Cancer biotherapy & radiopharmaceuticals.

Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.

G. Denardo, S. Denardo, P. Carter, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor.

G. Denardo, S. Denardo, C. Meares, 1998, Hybridoma.

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

acid (DOTA)-.Peptide-ChL6, a Novel linmunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2- (p-(Bromoacetamido)benzyl)-DOTA-ChL6 in Breast Cancer Xenografts'

K. Lamborn, G. Denardo, S. Denardo, 1998 .

Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy 1

Č. Venclovas, K. Lamborn, G. Denardo, 2003 .

Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.

Č. Venclovas, K. Lamborn, G. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer

K. Lamborn, G. Denardo, S. Denardo, 1992 .

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

K. Lamborn, G. Denardo, S. Denardo, 1997, Anticancer research.

The biologic window for chimeric l6 radioimmunotherapy

K. Lamborn, G. Denardo, S. Denardo, 1994, Cancer.

RADIOIMMUNOTHERAPY STUDIES IN BREAST CANCER

G. Denardo, S. Denardo, I. Hellstrom, 1992 .

The Evolving Role of the Medical Radiation Safety Officer

L. Kroger, Kendall Berry, D. Elder, 2018, Health physics.

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

J. McGahan, K. Lamborn, G. Denardo, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

G L DeNardo, K. Lamborn, G. Denardo, 1997, Cancer.

Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody

G. Denardo, S. Denardo, G. Adams, 1992 .

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

K. Lamborn, G. Denardo, L. Miers, 2003, Blood.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

J. McGahan, K. Lamborn, G. Denardo, 1998, Cancer biotherapy & radiopharmaceuticals.

G. Denardo, S. Denardo, P. Gumerlock, 2001, Cancer biotherapy & radiopharmaceuticals.

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.

G. Denardo, S. Denardo, L. Miers, 1998, Cancer biotherapy & radiopharmaceuticals.

Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.

G. Denardo, S. Denardo, P. Gumerlock, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Nuclear/radiological terrorism: emergency department management of radiation casualties.

J. Bushberg, E. Leidholdt, R. Derlet, 2007, The Journal of emergency medicine.

Radioimmunolocalization of breast cancer using BrE-3 monoclonal antibody.

R. Ceriani, S. Denardo, S. Glenn, 1994, Advances in experimental medicine and biology.

Characterization of human IgG antimouse antibody in patients with B-cell malignancies.

K. Lamborn, G. Denardo, S. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.

K. Lamborn, O. Schillaci, G. Denardo, 2007, Cancer biotherapy & radiopharmaceuticals.

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Clinical lymphoma.

Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.

G. Denardo, S. Denardo, S. Glenn, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A new era for radiolabeled antibodies in cancer?

G. Denardo, S. Denardo, L. Kroger, 1999, Current opinion in immunology.

Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1

K. Lamborn, G. Mirick, S. J. De Nardo, 1995, The International journal of biological markers.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

G. Denardo, S. Shen, D. Kukis, 1999, Cancer biotherapy & radiopharmaceuticals.

L6 monoclonal antibody binds prostate cancer

G. Denardo, S. Denardo, F. Meyers, 1998, The Prostate.

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

K. Lamborn, G. Denardo, S. Denardo, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

G. Denardo, S. Denardo, S. Shen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Milestones in the development of Lym-1 therapy.

G. Denardo, S. Denardo, G. Mirick, 1999, Hybridoma.

Nuclear/radiological terrorism: emergency department management of radiation casualties.

J. Bushberg, E. Leidholdt, R. Derlet, 2007, The Journal of emergency medicine.